| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
cis-10-Heptadecenoic acid targets cancer cells, particularly HL-60 leukemia cells, with an IC50 of 302 µM for inhibiting cell proliferation. It also targets macrophages, preventing LPS-induced tumor necrosis factor production. As a monounsaturated fatty acid, it may have beneficial effects on reducing inflammation and improving cholesterol profiles. Its plant metabolite role suggests interactions with plant metabolic pathways. Further research is needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that cis-10-Heptadecenoic acid inhibits HL-60 cell proliferation with an IC50 of 302 µM. The compound prevents LPS-induced tumor necrosis factor production from mouse macrophages. As a monounsaturated fatty acid, it may have beneficial effects on reducing inflammation. These in vitro findings support its potential applications in cancer and inflammation research.
|
| ln Vivo |
In vivo studies of cis-10-Heptadecenoic acid are limited as the compound is primarily used as a research chemical. As a minor constituent of ruminant fats, it is consumed in the diet. Its antitumor and anti-inflammatory properties suggest potential for in vivo evaluation in cancer and inflammation models. However, comprehensive in vivo pharmacological studies specifically targeting cis-10-Heptadecenoic acid are not well documented.
|
| Enzyme Assay |
In vitro enzyme assays for cis-10-Heptadecenoic acid typically involve testing its antitumor and anti-inflammatory activities. Antitumor activity is assessed using cell viability assays in cancer cell lines such as HL-60, with an IC50 of 302 µM. Anti-inflammatory activity is assessed by measuring inhibition of LPS-induced TNF-α production in macrophages. The compound's purity (≥99%) and identity are confirmed using analytical chemistry methods.
|
| Cell Assay |
In vitro cell-based assays for cis-10-Heptadecenoic acid involve culturing HL-60 leukemia cells to evaluate its antitumor activity. Cells are treated with varying concentrations of the compound and cell viability is assessed using MTT or similar colorimetric assays. For anti-inflammatory studies, mouse macrophages are treated with the compound and stimulated with LPS; TNF-α production is measured by ELISA. Cell viability is assessed to ensure observed effects are not due to cytotoxicity.
|
| Animal Protocol |
In vivo animal experiments for cis-10-Heptadecenoic acid would be conducted to evaluate its antitumor and anti-inflammatory activities. For antitumor studies, tumor-bearing animals would be treated and tumor growth monitored. For anti-inflammatory studies, animals with induced inflammation would be treated and inflammatory markers measured. Parameters assessed would include tumor growth, cytokine levels, and histopathology. Control groups receiving vehicle alone would be included for comparison.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of cis-10-Heptadecenoic acid reflect its nature as a monounsaturated fatty acid. It has a molecular weight of 268.43 and the molecular formula C17H32O2. As a fatty acid, it would be absorbed through the gastrointestinal tract and metabolized through standard fatty acid oxidation pathways. The compound has a purity of ≥99%. Complete pharmacokinetic profiling would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of cis-10-Heptadecenoic acid has been evaluated in the context of its use as a research chemical. As a naturally occurring fatty acid found in ruminant fats, it is expected to have a favorable safety profile at research concentrations. The compound has a purity of ≥99%. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References |
[1]. Robert J, et al. Analysis of the beta-oxidation of trans-unsaturated fatty acid in recombinant Saccharomyces cerevisiae expressing a peroxisomal PHA synthase reveals the involvement of a reductase-dependent pathway. Biochim Biophys Acta. 2005 May 15;1734(2):169-77.
|
| Additional Infomation |
(10Z)-Heptadecanoic acid is the cis isomer of 10-heptadecenoic acid. It is a plant metabolite and the conjugate acid of (10Z)-heptadecenoic acid ester.
cis-10-Heptadecenoic acid (CAS# 29743-97-3) is also known as (Z)-10-heptadecenoic acid. It has the molecular formula C17H32O2 and a molecular weight of 268.43. The compound is a monounsaturated fatty acid and a minor constituent of ruminant fats. It has a role as a plant metabolite. cis-10-Heptadecenoic acid inhibits HL-60 cell proliferation (IC50: 302 µM) and prevents LPS-induced TNF-α production. It has a purity of ≥99%. |
| Molecular Formula |
C17H32O2
|
|---|---|
| Molecular Weight |
268.43
|
| Exact Mass |
268.24
|
| CAS # |
29743-97-3
|
| Related CAS # |
trans-10-Heptadecenoic acid;126761-43-1
|
| PubChem CID |
5312435
|
| Appearance |
Colorless to light yellow liquid（Density：0.902±0.06 g/cm3）
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
354.0±11.0 °C at 760 mmHg
|
| Flash Point |
250.9±14.4 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.466
|
| LogP |
7.17
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
19
|
| Complexity |
221
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCC/C=C\CCCCCCCCC(=O)O
|
| InChi Key |
GDTXICBNEOEPAZ-FPLPWBNLSA-N
|
| InChi Code |
InChI=1S/C17H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(18)19/h7-8H,2-6,9-16H2,1H3,(H,18,19)/b8-7-
|
| Chemical Name |
(Z)-heptadec-10-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7254 mL | 18.6268 mL | 37.2537 mL | |
| 5 mM | 0.7451 mL | 3.7254 mL | 7.4507 mL | |
| 10 mM | 0.3725 mL | 1.8627 mL | 3.7254 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
